Youcare Pharmaceutical Group Past Earnings Performance
Past criteria checks 4/6
Youcare Pharmaceutical Group's earnings have been declining at an average annual rate of -17.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 1.6% per year. Youcare Pharmaceutical Group's return on equity is 6.6%, and it has net margins of 5.7%.
Key information
-17.7%
Earnings growth rate
-22.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -1.6% |
| Return on equity | 6.6% |
| Net Margin | 5.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Youcare Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,230 | 242 | 1,754 | 381 |
| 30 Jun 24 | 3,946 | 96 | 1,693 | 390 |
| 31 Mar 24 | 4,036 | 169 | 1,819 | 364 |
| 31 Dec 23 | 4,196 | 185 | 1,969 | 352 |
| 30 Sep 23 | 3,998 | 152 | 1,891 | 314 |
| 30 Jun 23 | 4,813 | 402 | 2,290 | 318 |
| 31 Mar 23 | 4,770 | 357 | 2,288 | 344 |
| 31 Dec 22 | 4,542 | 335 | 2,234 | 344 |
| 30 Sep 22 | 5,123 | 507 | 2,617 | 363 |
| 30 Jun 22 | 4,763 | 473 | 2,438 | 305 |
| 31 Mar 22 | 4,987 | 539 | 2,582 | 241 |
| 31 Dec 21 | 4,966 | 545 | 2,572 | 200 |
| 30 Sep 21 | 4,879 | 562 | 2,538 | 146 |
| 30 Jun 21 | 4,789 | 523 | 2,506 | 136 |
| 31 Mar 21 | 4,481 | 476 | 2,299 | 137 |
| 31 Dec 20 | 4,339 | 442 | 2,176 | 128 |
| 30 Sep 20 | 4,096 | 358 | 2,058 | 116 |
| 31 Dec 19 | 4,288 | 285 | 2,052 | 126 |
| 31 Dec 18 | 3,983 | 268 | 1,875 | 98 |
| 31 Dec 17 | 2,700 | 162 | 779 | 82 |
Quality Earnings: 688658 has high quality earnings.
Growing Profit Margin: 688658's current net profit margins (5.7%) are higher than last year (3.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688658's earnings have declined by 17.7% per year over the past 5 years.
Accelerating Growth: 688658's earnings growth over the past year (59.4%) exceeds its 5-year average (-17.7% per year).
Earnings vs Industry: 688658 earnings growth over the past year (59.4%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 688658's Return on Equity (6.6%) is considered low.